SAN DIEGO, May 4, 2017 /PRNewswire/ -- GenomeDx Biosciences today announced that seven abstracts featuring the company's Decipher® Genomics Resource Information Database (Decipher GRID®), Decipher Prostate Cancer Classifier and Decipher Bladder Cancer Classifier will be presented at the American Urological Association (AUA) 2017 Annual Meeting held May 12-16 in Boston, MA. The AUA meeting is the largest gathering of urologists in the world, showcasing the latest advances in urologic medicine and offering unparalleled access to groundbreaking research.
The abstract titled "The Diverse Genomic Landscape of Low-risk Prostate Cancer" was chosen as a Best Abstract, and will be presented as detailed below.
Oral Presentations
Title: Prospective study of biopsy Decipher scores in potential candidates for active surveillance
Date: Saturday, May 13 (2:40 p.m. to 2:50 p.m. EST)
Presentation Number: PD28-11
Room: BCEC - Room 205BC
Presenter: Stacy Loeb, M.D., MSc, New York University
Title: The Diverse Genomic Landscape of Low-risk Prostate Cancer
Date: Monday, May 15 (10:15 a.m. to 10:20 a.m. EST)
Presentation Number: PNFBA-09
Room: BCEC - Ballroom East
Presenter: Matthew Cooperberg, M.D., M.P.H., University of California, San Francisco
Title: Decipher Test Impacts Decision-Making among Patients Considering Adjuvant and Salvage Treatment following Radical Prostatectomy: Interim Results from the Multicenter Prospective PRO-IMPACT Study
Date: Tuesday, May 16 (9:30 a.m. to 9:40 a.m. EST)
Presentation Number: PD71-01
Room: BCEC - Room 162
Presenter: John L. Gore, M.D., M.S., University of Washington School of Medicine
Title: Genomic Classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation in patients with prostate cancer: Development and internal validation of a multivariable prognostic model
Date: Tuesday, May 16 (9:40 a.m. to 9:50 a.m. EST)
Presentation Number: PD72-02
Room: BCEC - Room 205BC
Presenter: Deepansh Dalela M.D., Henry Ford Health System
Poster Presentations
Title: Molecular subtypes of muscle invasive bladder cancer are related to benefit from neoadjuvant chemotherapy: Development of a single sample patient assay
Date: Saturday, May 13 (9:30 a.m. to 11:30 a.m. EST)
Presentation Number: MP34-01
Room: BCEC - Room 253AB
Presenter: Roland Seiler, M.D., University of British Columbia - Vancouver
Title: Development and validation of novel genomic classifiers for prediction of adverse pathology after prostatectomy
Date: Sunday, May 14 (1:00 p.m. to 3:00 p.m. EST)
Presentation Number: MP57-18
Room: BCEC - Room 153
Presenter: Firas Abdollah, M.D., Henry Ford Health System
Title: Assessing Decipher for predicting lymph node positive disease among men diagnosed with intermediate risk disease treated with prostatectomy and ePLND
Date: Sunday, May 14 (3:30 p.m. to 5:30 p.m. EST)
Presentation Number: MP64-12
Room: BCEC - Room 156
Presenter: John Davis, M.D., MD Anderson Cancer Center
About Decipher GRID® and Cancer Classifier Tests
GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
More information is available at www.deciphertest.com and www.deciphergrid.com
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com
SOURCE GenomeDx Biosciences